Next Article in Journal
Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
Previous Article in Journal
The Tobacco Endgame—A New Paradigm for Smoking Cessation in Cancer Clinics
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report

1
Cancer Center, The First Hospital of Jilin University, Changchun 130021, China
2
Pathology Department, The First Hospital of Jilin University, Changchun 130021, China
3
Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun 130021, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Curr. Oncol. 2022, 29(9), 6334-6341; https://doi.org/10.3390/curroncol29090498
Submission received: 22 June 2022 / Revised: 20 August 2022 / Accepted: 30 August 2022 / Published: 1 September 2022

Abstract

Carcinoma ex pleomorphic adenoma (Ca ex PA) is a rare malignant tumor that arises from a primary or recurrent benign pleomorphic adenoma (PA). Ca ex PA has an aggressive behavior and poor prognosis. To date, there are no standardized therapeutic methods. Herein, we reported a case of a 57-year-old Chinese female with Ca ex PA of the submandibular gland. After surgery, cervical lymph nodes recurred, and multiple distant metastases were detected. During the treatment, she received multiple chemotherapies and radiotherapy but suffered from multidrug resistance and repeated disease progression. Hence, PD-1 inhibitor (sintilimab), in combination with anlotinib, was administered, which resulted in better control of pulmonary metastases compared to the other treatment regimens. This provided an alternative treatment option for Ca ex PA of the submandibular gland patients with failed multiple therapies.
Keywords: carcinoma ex pleomorphic adenoma; submandibular gland; immunotherapy; antiangiogenic therapy carcinoma ex pleomorphic adenoma; submandibular gland; immunotherapy; antiangiogenic therapy

Share and Cite

MDPI and ACS Style

Sa, H.; Xu, Y.; Ma, X.; Wang, X.; Sun, C.; Qiu, S.; Guo, Y.; Yang, Z.; Liu, Y.; Ma, K. Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report. Curr. Oncol. 2022, 29, 6334-6341. https://doi.org/10.3390/curroncol29090498

AMA Style

Sa H, Xu Y, Ma X, Wang X, Sun C, Qiu S, Guo Y, Yang Z, Liu Y, Ma K. Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report. Current Oncology. 2022; 29(9):6334-6341. https://doi.org/10.3390/curroncol29090498

Chicago/Turabian Style

Sa, Huanlan, Yinghui Xu, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, and Kewei Ma. 2022. "Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report" Current Oncology 29, no. 9: 6334-6341. https://doi.org/10.3390/curroncol29090498

APA Style

Sa, H., Xu, Y., Ma, X., Wang, X., Sun, C., Qiu, S., Guo, Y., Yang, Z., Liu, Y., & Ma, K. (2022). Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report. Current Oncology, 29(9), 6334-6341. https://doi.org/10.3390/curroncol29090498

Article Metrics

Back to TopTop